Table 1.
Baseline characteristics of HGG patients (n = 142).
| Characteristics | Mean/median (standard deviation/95% CI), n (%) |
|---|---|
| Age (years) | 47.47 (14.35) |
| Radiation dose (Gy) | 58.92 (5.91) |
| PFS (months) | 345 (382–538) |
| OS (months) | 540 (561–720) |
|
| |
| Gender | |
| Female | 63 (44.37%) |
| Male | 79 (55.63%) |
|
| |
| IDH (N = 64) | |
| Wild | 45 (69.35%) |
| Mutation | 19 (30.65%) |
|
| |
| Histopathology | |
| Anaplastic oligodendroglioma | 43 (30.28%) |
| Anaplastic astrocytoma | 30 (21.13%) |
| Anaplastic pleomorphic xanthoastrocytoma | 5 (3.52%) |
| Glioblastoma | 64 (45.07%) |
|
| |
| Nonenhanced T2/FLAIR hyperintensity lesions | |
| Stable or decrease | 80 (54.93%) |
| Increase | 62 (45.07%) |
|
| |
| Enhancement of residual cavity wall | |
| Nonenhancement or thin-linear enhancement | 64 (45.07%) |
| Thick-linear or nodular enhancement | 78 (54.93%) |
|
| |
| PWI (N = 58) | |
| Progress | 47 (81.03%) |
| Stable | 11 (18.97%) |
|
| |
| NERF | |
| Negative | 70 (49.30%) |
| Positive | 72 (50.70%) |
|
| |
| nSVZE | |
| Negative | 65 (45.77%) |
| Positive | 77 (54.26%) |
|
| |
| Outcome | |
| Remain alive till due time | 90 (63.38%) |
| Dead | 52 (36.62%) |
HGG, high-grade glioma; CI, confidence interval; PFS, progression-free survival; OS, overall survival; IDH, isocitrate dehydrogenase; FLAIR, fluid-attenuated inversion recovery; NERF, new enhancement beyond the radiation field; nSVZE, new subventricular zone enhancement.